DispersinBĀ® Topical Wound Gel Manufacturing Completed

August 10, 2009

WINNIPEG, Manitoba (August 10, 2009) - Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that BioVectra has successfully completed the manufacturing of DispersinB® Topical Wound Gel under current Good Manufacturing Practices (cGMP). The required quality control (QC) tests including sterility and DispersinB® and alginate concentrations have been completed.

“The successful manufacturing represents a significant milestone in the development of a commercial product,” stated Dale Zajicek, Chief Operating Officer and Vice-President, Business Development for BioVectra. “BioVectra is honored to have been a part of this developing technology.”

“In addition to QC testing, we have also confirmed the biological activity of the DispersinB® Topical Wound Gel finished product based on its ability to inhibit as well as disperse bacterial biofilms using a standard biofilm assay,” stated Dr. Sri Madhyastha, Vice-President, Research & Chief Scientific Officer of Kane Biotech Inc. “The real-time shelf life and accelerated aging studies on the wound gel under cGMP are currently in progress”.

“The successful manufacturing of DispersinB® for human clinical trials is a critical step in the pathway to making a positive impact for patients suffering from chronic and poorly healing wounds”, stated Gord Froehlich, President and Chief Executive Officer of Kane Biotech Inc.

“With this step completed, we can now move forward and complete the DispersinB® Topical Wound Gel biocompatibility studies and work with our collaborators to design the regulatory approval program,” concluded Mr. Froehlich.

About BioVectra Inc.

BioVectra Inc. is a growing Canadian biopharmaceutical company focused on contract manufacturing and product development of active pharmaceutical ingredients, pharmaceutical intermediates and bioreagents. Located in Prince Edward Island, Canada, BioVectra currently holds 9 Drug Master File filings and is an active supplier to most of the major pharmaceutical, biotechnology, and diagnostic companies in North America and Europe. BioVectra is well positioned to provide full cGMP development and production expertise to the Canadian and World Biotech markets.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and remove biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and are involved in approximately 80% of all human bacterial infections. The healing of chronic wounds alone costs the United States health care system $20 Billion per year.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

For more information, please contact:
Gord Froehlich
President & Chief Executive Officer
Kane Biotech Inc.
204-477-7592 phone
204-453-1314 fax

Share This Story